Atlas Trials

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Clinical trial NCT06540937 · RECRUITING

Trial details

NCT number
NCT06540937
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2020-07-01
Primary completion
2024-12-30
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.